InflammaSense, a medtech company, has been awarded up to $38M by ARPA-H to use its VITALx-patch wearable sensor and ARC cascade-endotyping classifier to monitor autonomic and inflammatory signatures in critically ill patients.
Why it matters. The technology could improve the detection and treatment of critical illnesses like sepsis, potentially saving lives and reducing healthcare costs.
InflammaSense is a pre-revenue medtech company based in La Jolla, California, developing autonomic neurography (ANG) technology for real-time immune monitoring.
InflammaSense joins the program as a subaward performer under prime awardee the University of Vermont, working alongside UVM's Gary An on the ReSCUED effort within CIRCLE.
InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology
InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, today announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program receiving up to $38M to transform how clinicians…
Under the subaward, InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 severely critically ill patients across three clinical sites. Data will feed the company's Autonomic Research Core (ARC)…
LA JOLLA, Calif., Oct. 7, 2026 /PRNewswire/ -- InflammaSense, Inc., a pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, today announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program r…
